Clinical Trials

Aptar Digital Health announces acquisition of Healint

Aptar Digital Health, a global leader in digital health solutions (Software as a Medical Device (SaMD) and digital Patient Support Programs), connected devices and disease management, today announced that it has acquired Healint, a digital health company recognized for their virtual clinical studies, real-world evidence and patient registries platform, as well as the Migraine Buddy and Clarrio mobile apps, which support patients suffering from neurological and immunological conditions.

The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment. The expanded capabilities include patient community management, patient activation, Artificial Intelligence (AI) based data collection and analysis, as well as digital diagnostics to facilitate patient screening and identification. Furthermore, Healint’s ability to conduct clinical studies at an accelerated pace and at a global scale complements Aptar Digital Health’s existing solutions to provide additional value to pharmaceutical customers.

Founded in 2013, Healint is a pioneer in multimodal health and Quality of Life (QoL) tracking and clinically validated data collection, using self-input and sensor data at scale, interpreted via its proprietary AI. Healint generates real-world evidence for patients, physicians and researchers to improve treatment outcomes and expedite clinical trials. Healint has developed Migraine Buddy, the first patented migraine mobile app in the world, with over three million registered users.

Aptar Digital Health creates end-to-end solutions to enhance patient experiences every day, leveraging a holistic ecosystem of digital interventions. Aptar Digital Health’s offering combines mobile and web apps, connected drug delivery systems, onboarding, training and advanced data analytics services to actively empower patients and create a positive treatment journey.

“We are excited to welcome the Healint team and expand Aptar Digital Health’s product portfolio and capabilities to clinical trial management,” said Sai Shankar, President of Aptar Digital Health. “With Healint, we now have the in-house expertise to cover the entire lifecycle of a drug, positioning Aptar Digital Health as a prominent leader in digital health for Central Nervous System conditions.”

Stated François Cadiou, CEO and Founder of Healint, “We are delighted to join the Aptar Digital Health team to better serve patients, healthcare professionals and pharmaceutical companies. This acquisition will accelerate the development of our AI-powered precision medicine SaMD designed to augment existing treatment, thanks to unique datasets and scientific expertise.”

Gael Touya, President of Aptar Pharma, commented, “Through this acquisition, the combined expertise of Aptar Digital Health and Healint in developing state-of-the-art solutions that empower patients in their disease journey fully aligns with Aptar Pharma’s primary ambition of improving patient experiences and health outcomes.”

The integration of Healint into Aptar Digital Health’s operations will commence immediately. Aptar Digital Health will scale up Healint’s platform to adjacent therapeutic indications in neurology and immunology, and strengthen its current offering by adding new services such as clinical trial management tools.

Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!

Related posts

UCB and Veeva to Advance the Patient Experience in Clinical Trials

PR Newswire

OneOncology finalizes 25 Oncology and Hematology Pathways

PR Newswire

TWi Biotechnology Exploring Promising Treatment for GA

PR Newswire